No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|
No. = Number of; LABA= Long-acting beta-2-agonists; ATB=
antibiotics; BALF = Bronchoalveolar lavage fluid; PMN =
Polymorphonuclear cells; Norm. = normalized; RBM= Reticular basement
membrane; BSM = Bronchial smooth muscle.
Patients were divided according to the number of exacerbations in the
year following the fibreoptic bronchoscopy in No-Ex (0 exacerbation,
n=20), Low-Ex (1 or 2 exacerbations, n=27) and High-Ex (≥3
exacerbations, n=33) groups. Univariate associations with the number of
exacerbations during the year following fibreoptic bronchoscopy were
determined using simple multinomial regression and results were
expressed as reference group vs. compared group. For each parameter, the
odds ratio (OR) is presented with its 95% confidence interval. A
p value < 0.05 was considered significant (bold). Only
parameters with significant OR between No-Ex vs. Low-Ex (p1)
and/or No-Ex vs. High-Ex (p2) and/or Low-Ex vs. High-Ex
(p3) are presented. An OR<1 was in favour of the
reference group and an OR >1 was in favour of the compared
group. All others non-significant parameters are available in the
supplemental material (Table E2).
|